Invention Grant
- Patent Title: Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population
-
Application No.: US15455684Application Date: 2017-03-10
-
Publication No.: US10213426B2Publication Date: 2019-02-26
- Inventor: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Yi Zhu , James L. Kirkland , Tamar Tchkonia
- Applicant: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
- Applicant Address: US CA Brisbane US CA Novato US MN Rochester
- Assignee: UNITY BIOTECHNOLOGY, INC.,BUCK INSTITUE FOR RESEARCH ON AGING,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
- Current Assignee: UNITY BIOTECHNOLOGY, INC.,BUCK INSTITUE FOR RESEARCH ON AGING,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
- Current Assignee Address: US CA Brisbane US CA Novato US MN Rochester
- Agency: Wilson Sonsini Goodrich & Rosati
- Agent Michael Schiff; Janet Martineau
- Main IPC: G01N1/00
- IPC: G01N1/00 ; C12Q1/00 ; A61K31/496 ; A61K31/428 ; A61K31/495 ; A61K31/5377 ; A61K31/404 ; A61K31/4375 ; A61K45/06 ; A61K31/4178 ; A61K31/728 ; C12N5/00 ; A61K47/36 ; A61K9/00
Abstract:
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Public/Granted literature
Information query
